Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00499616
Registration number
NCT00499616
Ethics application status
Date submitted
10/07/2007
Date registered
11/07/2007
Date last updated
6/07/2021
Titles & IDs
Public title
Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma
Query!
Scientific title
Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma
Query!
Secondary ID [1]
0
0
COG-ANBL0531
Query!
Secondary ID [2]
0
0
ANBL0531
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Neuroblastoma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Neuroendocrine tumour (NET)
Query!
Cancer
0
0
0
0
Query!
Children's - Other
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - carboplatin
Treatment: Drugs - cyclophosphamide
Treatment: Drugs - doxorubicin hydrochloride
Treatment: Drugs - etoposide
Treatment: Drugs - topotecan hydrochloride
Treatment: Drugs - Isotretinoin
Treatment: Surgery - Surgery
Treatment: Drugs - Filgrastim
Experimental: Group 2 (chemotherapy, surgery) - 2 courses of initial chemotherapy (6 wks) - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. Partial response (PR) to chemo go to observation. No PR: 2-6 additional courses of chemo (beginning course 3 - cyclophosphamide, etoposide, filgrastim, carboplatin, doxorubicin hydrochloride). No PR after additional chemotherapy proceed to retrieval chemo: cyclophosphamide and topotecan hydrochloride on days 1-5. Treatment with retrieval chemotherapy repeats every 21 days for up to 6 courses. Some patients may also undergo surgery.
Experimental: Group 3 (chemotherapy, surgery) - 4 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, filgrastim. Patients with a PR after chemo proceed to observation. No PR receive 2-4 additional courses of chemotherapy (beginning with course 5) - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. No PR after additional chemo proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.
Experimental: Group 4 (chemotherapy, surgery, antineoplastic therapy) - 8 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. Patients \< 12 months of age with stg 3, 4, or 4S (not including liver metastases) disease who achieve a very good PR (VGPR) to chemo proceed to observation. Patients 12-18 months of age with stg 3 or 4 who achieve VGPR proceed to isotretinoin therapy. No VGPR proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.
Experimental: Non-intermediate risk enrolled on intermediate risk trial - The no treatment group assignment patients may have received some treatment on ANBL0531 but they were not evaluable on this study due to being non-intermediate risk and hence did not receive a treatment assignment on ANBL0531.
Treatment: Drugs: carboplatin
Given IV
Treatment: Drugs: cyclophosphamide
Given IV
Treatment: Drugs: doxorubicin hydrochloride
Given IV
Treatment: Drugs: etoposide
Given orally
Treatment: Drugs: topotecan hydrochloride
Given IV
Treatment: Drugs: Isotretinoin
Given orally
Treatment: Surgery: Surgery
With the exception of patients with INSS 4S disease, patients undergo surgery to remove as much of the primary tumor and involved lymph nodes as can safely be accomplished.
Treatment: Drugs: Filgrastim
Administered subcutaneously or by IV beginning 24-48 hrs after the last dose of chemotherapy \& continuing daily until the ANC is greater than or equal to 1500 following the myelosuppressive nadir . Supportive care given to stimulate neutrophil recovery following chemotherapy and to shorten the duration of chemotherapy-induced neutropenia. On ANBL0531 the use of filgrastim was required for patients less than 60 days of age and was optional for other patients.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Intervention code [2]
0
0
Treatment: Surgery
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Overall Survival (OS) Rates
Query!
Assessment method [1]
0
0
OS time is calculated from date of enrollment until death, or until last contact if the patient is alive.
Query!
Timepoint [1]
0
0
3 years
Query!
Primary outcome [2]
0
0
Definitive Determination of the Prognostic Ability of 1p and 11q
Query!
Assessment method [2]
0
0
Addressed by a descriptive comparison of the EFS and OS rates for patients with 1p loss vs without 1p loss, and for those with unbalanced 11q vs normal 11q.
Query!
Timepoint [2]
0
0
At baseline
Query!
Primary outcome [3]
0
0
Comparison Between Reduce Intensity of Therapy for Patients With Stage 4 Neuroblastoma and Favorable Biological Features and Patients < 1 Year of Age With Stage 4 Neuroblastoma Treated on COG-A3961
Query!
Assessment method [3]
0
0
Addressed by the interim stopping rule and the comparison, by INSS stage, to the historical EFS rate of the analogous cohort of patients \< 1 yrs of age.
Query!
Timepoint [3]
0
0
Up to 3 years
Query!
Primary outcome [4]
0
0
Comparison Between Reduce Intensity of Therapy for Patients With Unfavorable Histology Neuroblastoma and Patients Unfavorable Histology Neuroblastoma Treated on COG-A3961
Query!
Assessment method [4]
0
0
Addressed by the interim stopping rule and the comparison, by INSS stage, to the historical EFS rate of the analogous cohort of patients \< 1 yrs of age
Query!
Timepoint [4]
0
0
Up to 3 years
Query!
Primary outcome [5]
0
0
Reduced Surgical Morbidity for Patients With Stage 4S Neuroblastoma
Query!
Assessment method [5]
0
0
Descriptive analyses of the proportion of stage 4S infants that experience a surgical or post-operative event.
Query!
Timepoint [5]
0
0
Up to 3 years
Query!
Primary outcome [6]
0
0
Outcome of Patients With Stage 4S Neuroblastoma Who Are Unable to Undergo Biopsy for Biology-based Risk Assignment
Query!
Assessment method [6]
0
0
Kaplan-Meier curves and lifetables of Event Free Survival (EFS) and Overall Survival (OS) rates will be generated to describe the outcome of the stage 4S infants unable to undergo biopsy.
Query!
Timepoint [6]
0
0
From baseline to up to 10 years
Query!
Primary outcome [7]
0
0
Correlation Between Extent of Surgical Resection With the Maintenance of Local Control, Event Free Survival (EFS)
Query!
Assessment method [7]
0
0
To test the predictive ability of the extent of surgical resection for EFS, log-rank tests will be performed comparing complete surgical resection vs. without complete surgical resection.
Query!
Timepoint [7]
0
0
Up to 10 years
Query!
Primary outcome [8]
0
0
Correlation Between Extent of Surgical Resection With the Maintenance of Local Control, Overall Survival (OS) Rates
Query!
Assessment method [8]
0
0
To test the predictive ability of the extent of surgical resection for OS, log-rank tests will be performed comparing complete surgical resection vs. without complete surgical resection.
Query!
Timepoint [8]
0
0
Up to 10 years
Query!
Primary outcome [9]
0
0
Correlation Between Extent of Surgical Resection With the Maintenance of Local Control, Surgical Complication Rate
Query!
Assessment method [9]
0
0
To test for the association of the extent of surgical resection (CR vs \<CR) with surgical complications rate (complications of any kind vs no complications at all), a chi-square test will be performed.
Query!
Timepoint [9]
0
0
Up to 10 years
Query!
Secondary outcome [1]
0
0
Second-event-free Survival (E2FS)
Query!
Assessment method [1]
0
0
E2FS (from time of first event) will be calculated to describe the outcome for patients who have a first progressive, non-metastatic event during Observation and then receive protocol retrieval therapy.
Query!
Timepoint [1]
0
0
From the time of the first progressive, non-metastatic event until the subsequent occurrence of relapse, progressive disease, secondary malignancy, or death; up to 3 years
Query!
Secondary outcome [2]
0
0
Second-Overall Survival
Query!
Assessment method [2]
0
0
OS (from the time of first event) will be calculated to describe the outcome for patients who have a first progressive, non-metastatic event during Observation and then receive protocol retrieval therapy.
Query!
Timepoint [2]
0
0
From the time of the first progressive, non-metastatic event; up to 3 years
Query!
Secondary outcome [3]
0
0
Biological Surrogate Markers
Query!
Assessment method [3]
0
0
Multivariable analyses will be performed to identify variables of prognostic interest.
Query!
Timepoint [3]
0
0
At baseline and surgery
Query!
Secondary outcome [4]
0
0
Neurologic Symptoms
Query!
Assessment method [4]
0
0
Percentage of patients with neurologic symptoms will be calculated. Includes patients with paraspinal or intraspinal tumors, including epidural tumors with or without spinal cord compression. Neurologic symptoms include back or extremities neurologic symptoms, motor deficit, abnormal sensation, abnormal bladder/bowel sphincteric function, chronic pain in back or extremities, scoliosis, kyphosis, or clinically relevant/functional abnormality in size or contour of leg or foot.
Query!
Timepoint [4]
0
0
At baseline
Query!
Secondary outcome [5]
0
0
Association Between Surgical Biopsy Technique With Adequacy of Tissue Acquisition for Biologic Studies, and With Complications Associated With the Biopsy Procedure
Query!
Assessment method [5]
0
0
A chi-square test will be performed.
Query!
Timepoint [5]
0
0
During and after surgery
Query!
Secondary outcome [6]
0
0
Image Defined Risk Factor (IDRF)
Query!
Assessment method [6]
0
0
Percentage of patients with presence of one or more IDRFs will be calculated. IDRFs describe anatomic features which may make surgical resection more difficult.
Query!
Timepoint [6]
0
0
At baseline
Query!
Eligibility
Key inclusion criteria
DISEASE CHARACTERISTICS:
* Histologically confirmed neuroblastoma, ganglioneuroblastoma, or ganglioneuroma/maturing subtype
* Newly diagnosed disease
* Intermediate-risk disease
* Needle biopsies or involved bone marrow are not sufficient for INPC histologic classification
* Meets 1 of the following criteria:
* Group 2
* International Neuroblastoma Staging System (INSS) stage 2A/2B; < 50% resected or biopsy only; = 12 years of age; MYCN-not amplified (NA); any histology and ploidy; normal 1p and 11q
* INSS stage 3; age < 365 days; MYCN-NA; favorable histology (FH); hyperdiploid (DI) > 1; normal 1p and 11q
* INSS stage 3; 365 days to 12 years of age; MYCN-NA; FH; normal 1p and 11q
* INSS stage 4S; age < 365 days; MYCN-NA; FH; DI >1; normal 1p and 11q; clinically symptomatic
* Group 3
* INSS stage 2A/2B; < 50% resected or biopsy only; = 12 years of age; MYCN-NA; any histology and ploidy; 1p loss of heterozygosity (LOH) and/or unb11q LOH (or data missing for either)
* INSS stage 3; age < 365 days; MYCN-NA; FH; DI > 1; 1p LOH and/or unb11q LOH (or data missing for either)
* INSS stage 3; age < 365 days; MYCN-NA; DI = 1 and/or unfavorable histology (UH); normal 1p and 11q
* INSS stage 3; 365 days to 12 years of age; MYCN-NA; FH; 1p LOH and/or unb11q LOH (or data missing for either)
* INSS stage 4; age < 365 days; MYCN-NA; FH; DI > 1; normal 1p and 11q
* INSS stage 4S; age < 365 days; MYCN-NA; either UH and any ploidy or FH and DI = 1; normal 1p and 11q
* INSS stage 4S; age < 365 days; MYCN-NA; FH; DI > 1; 1p LOH and/or unb11q LOH (or data missing for either); clinically symptomatic
* Group 4
* INSS stage 3; age < 365 days; MYCN-NA; DI = 1 and/or UH; 1p LOH and/or unb11q LOH (or data missing for either)
* INSS stage 3; age 365 to < 547 days; MYCN-NA; UH; any ploidy; any 1p and 11q
* INSS stage 4, age < 365 days; MYCN-NA; DI = 1 and/or UH; any 1p and 11q
* INSS stage 4; age < 365 days; MYCN-NA; FH; DI > 1; 1p LOH and/or unb11q LOH (or data missing for either)
* INSS stage 4; age 365 to < 547 days; MYCN-NA; FH; DI > 1; any 1p and 11q
* INSS stage 4S; age < 365 days; MYCN-NA; UH and any ploidy or FH and DI = 1; 1p LOH and/or unb11q LOH (or data missing for either)
* INSS stage 4S; age < 365 days; unknown or incomplete biologic features
8 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim.
Patients < 12 months of age with stg 3, 4, or 4S disease who achieve a very good PR (VGPR) to chemo (with the exception of resolution of skin or liver metastases in stage 4S patients) proceed to observation. Patients 12-18 months of age with stg 3 or 4 who achieve VGPR proceed to isotretinoin therapy. No VGPR proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.
* Must already be enrolled on protocol COG-ANBL00B1
* Simultaneous enrollment on COG-ANBL00B1 and this study allowed for clinical situations in which emergent treatment may be indicated including, but not limited to, the following criteria:
* Epidural or intraspinal tumors with existing or impending neurologic impairment
* Periorbital or calvarial-based lesions with existing or impending cranial nerve impairment
* Anatomic or mechanical compromise of critical organ function by tumor (e.g., abdominal compartment syndrome, urinary obstruction)
* Asymptomatic but, in the opinion of the treating physician, it is in the patient's best interest to begin chemotherapy immediately due to impending risk of neurologic impairment or organ dysfunction
* If patient receives study chemotherapy prior to undergoing diagnostic biopsy, the biopsy must be performed within 96 hours of beginning study therapy
* The only exception to this requirement is for patients with stage 4S disease who are considered too ill to undergo a diagnostic procedure will be waived the requirement for diagnostic tissue submission but will still need to be enrolled on COG-ANBL00B1
* For patients with stage 4S disease who are very ill and in whom an open biopsy to obtain tissue for diagnosis and biologic studies is considered medically contraindicated, every effort should be made to obtain some tumor tissue by either fine-needle aspiration of a metastatic site of disease and/or sampling of involved bone marrow, so that this tumor sample can be submitted for MYCN determination
* Patients who require emergent therapy, either prior to the diagnostic biopsy or before biology features are available, can be enrolled simultaneously on COG-ANBL00B1 and COG-ANBL0531 to receive emergent protocol therapy
* In emergent circumstances, COG-ANBL0531 protocol therapy may be initiated prior to enrollment on study as long as the patient has neuroblastoma by clinical diagnosis, all other COG-ANBL0531 eligibility criteria are met, and the COG-ANBL0531 Initial Therapy consent has been signed prior to starting protocol therapy; in this circumstance ANBL0531 enrollment must occur within 4 working days of starting protocol therapy
* Clinical situations in which emergent enrollment and treatment may be indicated include, but are not limited to, the following circumstances:
* Epidural or intraspinal tumors with existing or impending neurologic impairment
* Periorbital or calvarial-based lesions with existing or impending cranial nerve impairment
* Anatomic or mechanical compromise of critical organ function by tumor (e.g., abdominal compartment syndrome, urinary obstruction)
* Evolving hepatomegaly in infants less than 2 months of age
PATIENT CHARACTERISTICS:
* See Disease Characteristics
PRIOR CONCURRENT THERAPY:
* See Disease Characteristics
* No other prior chemotherapy or radiotherapy with the exception of dexamethasone
* No participation in another COG study with tumor therapeutic intent
Query!
Minimum age
No limit
Query!
Query!
Maximum age
12
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
8/10/2007
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
30/06/2021
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
464
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,WA
Query!
Recruitment hospital [1]
0
0
Children's Hospital at Westmead - Westmead
Query!
Recruitment hospital [2]
0
0
Royal Children's Hospital - Brisbane
Query!
Recruitment hospital [3]
0
0
Women's and Children's Hospital - North Adelaide
Query!
Recruitment hospital [4]
0
0
Princess Margaret Hospital for Children - Perth
Query!
Recruitment postcode(s) [1]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [2]
0
0
4029 - Brisbane
Query!
Recruitment postcode(s) [3]
0
0
5006 - North Adelaide
Query!
Recruitment postcode(s) [4]
0
0
6001 - Perth
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Arkansas
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
California
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Colorado
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Connecticut
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Delaware
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
District of Columbia
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Florida
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Georgia
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Hawaii
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Idaho
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Illinois
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Indiana
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Iowa
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Kentucky
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Louisiana
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Maine
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Maryland
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Massachusetts
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Michigan
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Minnesota
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Mississippi
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Missouri
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Nebraska
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Nevada
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
New Hampshire
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
New Jersey
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
New Mexico
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
New York
Query!
Country [31]
0
0
United States of America
Query!
State/province [31]
0
0
North Carolina
Query!
Country [32]
0
0
United States of America
Query!
State/province [32]
0
0
Ohio
Query!
Country [33]
0
0
United States of America
Query!
State/province [33]
0
0
Oklahoma
Query!
Country [34]
0
0
United States of America
Query!
State/province [34]
0
0
Oregon
Query!
Country [35]
0
0
United States of America
Query!
State/province [35]
0
0
Pennsylvania
Query!
Country [36]
0
0
United States of America
Query!
State/province [36]
0
0
Rhode Island
Query!
Country [37]
0
0
United States of America
Query!
State/province [37]
0
0
South Carolina
Query!
Country [38]
0
0
United States of America
Query!
State/province [38]
0
0
South Dakota
Query!
Country [39]
0
0
United States of America
Query!
State/province [39]
0
0
Tennessee
Query!
Country [40]
0
0
United States of America
Query!
State/province [40]
0
0
Texas
Query!
Country [41]
0
0
United States of America
Query!
State/province [41]
0
0
Utah
Query!
Country [42]
0
0
United States of America
Query!
State/province [42]
0
0
Vermont
Query!
Country [43]
0
0
United States of America
Query!
State/province [43]
0
0
Virginia
Query!
Country [44]
0
0
United States of America
Query!
State/province [44]
0
0
Washington
Query!
Country [45]
0
0
United States of America
Query!
State/province [45]
0
0
West Virginia
Query!
Country [46]
0
0
United States of America
Query!
State/province [46]
0
0
Wisconsin
Query!
Country [47]
0
0
Canada
Query!
State/province [47]
0
0
Alberta
Query!
Country [48]
0
0
Canada
Query!
State/province [48]
0
0
British Columbia
Query!
Country [49]
0
0
Canada
Query!
State/province [49]
0
0
Manitoba
Query!
Country [50]
0
0
Canada
Query!
State/province [50]
0
0
Newfoundland and Labrador
Query!
Country [51]
0
0
Canada
Query!
State/province [51]
0
0
Nova Scotia
Query!
Country [52]
0
0
Canada
Query!
State/province [52]
0
0
Ontario
Query!
Country [53]
0
0
Canada
Query!
State/province [53]
0
0
Quebec
Query!
Country [54]
0
0
Canada
Query!
State/province [54]
0
0
Saskatchewan
Query!
Country [55]
0
0
Netherlands
Query!
State/province [55]
0
0
Nijmegen
Query!
Country [56]
0
0
New Zealand
Query!
State/province [56]
0
0
Auckland
Query!
Country [57]
0
0
New Zealand
Query!
State/province [57]
0
0
Christchurch
Query!
Country [58]
0
0
Puerto Rico
Query!
State/province [58]
0
0
Santurce
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
Children's Oncology Group
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Government body
Query!
Name [1]
0
0
National Cancer Institute (NCI)
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
RATIONALE: Drugs used in chemotherapy, such as carboplatin, cyclophosphamide, etoposide, and doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Isotretinoin may help neuroblastoma cells become more like normal cells, and grow and spread more slowly. Giving combination chemotherapy before surgery may make the tumor smaller and make it more likely that the tumor can be surgically removed. It is not yet known what is the minimal amount of chemotherapy needed to achieve sufficient tumor shrinkage to control intermediate risk neuroblastoma and prevent tumor recurrence or metastases. PURPOSE: This phase III trial is designed to reduce therapy for patients with favorable biology intermediate risk neuroblastoma by decreasing the number of chemotherapy cycles administered and by allowing for up to 50% residual tumor volume for patients with localized disease.
Query!
Trial website
https://clinicaltrials.gov/study/NCT00499616
Query!
Trial related presentations / publications
Twist CJ, Schmidt ML, Naranjo A, London WB, Tenney SC, Marachelian A, Shimada H, Collins MH, Esiashvili N, Adkins ES, Mattei P, Handler M, Katzenstein H, Attiyeh E, Hogarty MD, Gastier-Foster J, Wagner E, Matthay KK, Park JR, Maris JM, Cohn SL. Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531. J Clin Oncol. 2019 Dec 1;37(34):3243-3255. doi: 10.1200/JCO.19.00919. Epub 2019 Aug 6. Twist CJ, Naranjo A, Schmidt ML, Tenney SC, Cohn SL, Meany HJ, Mattei P, Adkins ES, Shimada H, London WB, Park JR, Matthay KK, Maris JM. Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531. J Clin Oncol. 2019 Jan 10;37(2):115-124. doi: 10.1200/JCO.18.00419. Epub 2018 Nov 16.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clare Twist, MD
Query!
Address
0
0
Lucile Packard Children's Hospital at Stanford University Medical Center
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT00499616
Download to PDF